Last year GenomeDx Biosciences presented data showing that its Decipher® Prostate Cancer Classifier (the test), a genomic test, is capable of predicting the probability that a man will eventually develop metastatic prostate cancer, despite having surgery as a primary treatment for prostate cancer. The company claims that the test out performs other existing tests of clinical risk factors for predicting biochemical failure and the development of distant metastasis following primary surgery. In addition, researchers observed significant improvement in outcomes of those men with high risk Decipher results who received adjuvant radiation therapy earlier rather than later after surgery.
The data was presented at the 2014 American Society of Clinical Oncologists (ASCO) Genitourinary Symposium.
“This is the first validation of the Decipher test in patients receiving radiation therapy following prosta